Schermafbeelding 2018-09-30 om 17.52.18

The epiXchange conference took place May 23, 2018 in Brussels. The main goal of this conference was to showcase major findings from seven large European epilepsy research projects, amongst which the EPISTOP project. 

The full live stream of the epiXchange conference can be found by clicking here

An overview of the EPISTOP project was given by prof. S. Józwiak (21:29). 

Afterwards, EPISTOP was represented in the different thematic sessions:
1. Translational research in biomarkers
    "EEG changes as biomarker for emerging epilepsies in TSC" by prof. L. Lagae (1:28:26)

2. Genetics of epilepsy - Therapeutics implications
   
"Genetics and Mosaicism in Tuberous Sclerosis Complex: preliminary analysis of association with seizure phenotype in
     EPISTOP" by prof. D. Kwiatkowski (2:22:37)

3. Innovation Therapeutics & Translation
   
"Preseizure vs postseizure treatment of epilepsy - pros and cons" by prof. S. Józwiak (3:34:56)

4. Understanding Co-morbidities in the Epilepsies
 
  "Autism in Tuberous sclerosis: early developmental trajectories, potential biomarkers and treatment strategies" by prof. P.
     Curatolo (4:47:18)

5. Biobanks and Databases - Basis for Translational Research
   
"Biobanking in Tuberous Sclerosis Complex: challenges and opportunities for understanding epilepsy and cognitive and   
     behavioural co-morbidities" by prof. E. Aronica (6:05:57)

 

Below you can find the presentation of prof. S. Józwiak on the structure of the EPISTOP project:

Schermafbeelding 2018-09-30 om 18.11.46

Schermafbeelding 2018-09-30 om 17.56.45

Schermafbeelding 2018-09-30 om 17.57.02

Schermafbeelding 2018-09-30 om 17.57.17

Schermafbeelding 2018-09-30 om 17.57.31

DEA logo

On October 19-20, the Belgian TSC association (be-TSC) is hosting the 2018 DEA Pit Stop jointly with E-TSC, the European TSC Association. The focus will be on neurology, EPISTOP and TSC-associated Neuropsychiatric Disorders (TAND).

Leading researchers on this years topics include prof. Sergiusz Józwiak (EPISTOP) and prof. Petrus de Vries (TAND). Major contributions on the subject of behavioral issues will also be made by Lucy Wilde (PhD Bsc, University of Birmingham), dr. Agnies van Eeghen (MD PhD, Erasmus MC Rotterdam), the Dutch TSC- and- behavior Expertteam (ETSCG) and the TSC teams of the University hospitals Brussels (Prof. Anna Jansen) and Leuven (Prof. Liesbeth De Waele).

Registration to the DEA Pit Stop is free of charge. To confirm your participation simply email to This email address is being protected from spambots. You need JavaScript enabled to view it.

The full program can be found here.

Schermafbeelding 2018-10-20 om 15.42.08

 

banner TSCi conference

The international Tuberous Sclerosis Complex Research Conference (TSCi) recently took place in Tokyo, Japan on September 13-15, 2018.

The topics covered, ranged from mechanisms, over preventive and novel therapies to improving quality of life in TSC. 

EPISTOP was well represented during the different sessions through lectures given by prof. dr. S. Jozwiak, prof. dr. K. Kotulska, prof. dr. P. Curatolo, prof. dr. D. Kwiatkowski and prof. dr. A. Jansen.
Also, our EPISTOP movie was shown with japanese subtitles. 

 

picture TSCi 2

 

We are delighted to inform you that the next General Assembly meeting will take place on the 20th and 21st of October 2018 in Leuven, Belgium. 

Representatives of each Partner of EPISTOP project will attend the meeting. During the meeting, we are going to discuss the results per work package. Moreover sessions in groups - clinical group and molecular genetic group - will be organized. At the same time, an internal meeting of the members of the external Scientific Advisory Board (SAB) will take place. Minutes from the meeting will be published on the website in November.

 

EpiXchange brings together the excellence of epilepsy research in Europe for a conference in Brussels on 23rd of May 2018. The main goal is to showcase major findings from seven large European epilepsy research projects, discuss the main bottlenecks and recommendations to move forward and to bring research results closer to clinical application. 

Please find below the official press release. 

EPIXCHANGE press release p1

EPIXCHANGE press release p2